Prime, Shock and Kill: BCL-2 Inhibition for HIV Cure

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 7

PMID 36341439

Authors

Aswath P Chandrasekar

Andrew D Badley

Affiliations

Soon will be listed here.

Abstract

While modern HIV therapy can effectively suppress viral replication, the persistence of the latent reservoir posits the greatest hurdle to complete cure. The "shock and kill" strategy is under investigation for HIV therapy, aiming to reactivate latent HIV, and subsequently eliminate it through anti-retroviral therapy and host immune function. However, thus far, studies have yielded suboptimal results, stemming from a combination of ineffective latency reversal and poor immune clearance. Concomitantly, studies have now revealed the importance of the BCL-2 anti-apoptotic protein as a critical mediator of infected cell survival, reservoir maintenance and immune evasion in HIV. Furthermore, BCL-2 inhibitors are now recognized for their anti-HIV effects in pre-clinical studies. This minireview aims to examine the intersection of BCL-2 inhibition and current shock and kill efforts, hoping to inform future studies which may ultimately yield a cure for HIV.

Citing Articles

Youth Who Control HIV on Antiretroviral Therapy Display Unique Plasma Biomarkers and Cellular Transcriptome Profiles Including DNA Repair and RNA Processing.

Borkar S, Yin L, Venturi G, Shen J, Chang K, Fischer B Cells. 2025; 14(4).

PMID: 39996757 PMC: 11853983. DOI: 10.3390/cells14040285.

HIV persists in late coronary atheroma and is associated with increased local inflammation and disease progression.

Obare L, Bailin S, Zhang X, Nthenge K, Priest S, Liu Q Res Sq. 2024; .

PMID: 39483879 PMC: 11527356. DOI: 10.21203/rs.3.rs-5125826/v1.

Optimization of a lentivirus-mediated gene therapy targeting HIV-1 RNA to eliminate HIV-1-infected cells.

Buckingham A, Ho S, Knops-Mckim F, Ingemarsdotter C, Lever A Mol Ther Nucleic Acids. 2024; 35(4):102341.

PMID: 39434850 PMC: 11491724. DOI: 10.1016/j.omtn.2024.102341.

Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies.

Fert A, Richard J, Raymond Marchand L, Planas D, Routy J, Chomont N iScience. 2024; 27(9):110670.

PMID: 39252967 PMC: 11381840. DOI: 10.1016/j.isci.2024.110670.

Emerging roles of senolytics/senomorphics in HIV-related co-morbidities.

Kaur G, Rahman M, Shaikh S, Panda K, Chinnapaiyan S, Santiago Estevez M Biochem Pharmacol. 2024; 228():116179.

PMID: 38556028 PMC: 11410549. DOI: 10.1016/j.bcp.2024.116179.

References

Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias M, Martin M, Barbas C . Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016; 30(9):1385-92. DOI: 10.1097/QAD.0000000000001064. View

Zamai L, Ahmad M, M Bennett I, Azzoni L, Alnemri E, Perussia B . Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998; 188(12):2375-80. PMC: 2212426. DOI: 10.1084/jem.188.12.2375. View

Sutton V, Vaux D, Trapani J . Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol. 1997; 158(12):5783-90. View

Bachmann N, Von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N . Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019; 10(1):3193. PMC: 6642170. DOI: 10.1038/s41467-019-10884-9. View

Vereertbrugghen A, Colado A, Gargiulo E, Bezares R, Fernandez Grecco H, Cordini G . Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Front Oncol. 2021; 11:598319. PMC: 8350736. DOI: 10.3389/fonc.2021.598319. View

Cummins N, Jiang W, McGinty J, Bren G, Bosch R, Landay A . Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010; 202(3):386-91. PMC: 2906377. DOI: 10.1086/653705. View

Harwood O, OConnor S . Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection. Viruses. 2021; 13(9). PMC: 8473246. DOI: 10.3390/v13091750. View

Heibein J, Goping I, Barry M, Pinkoski M, Shore G, Green D . Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med. 2000; 192(10):1391-402. PMC: 2193181. DOI: 10.1084/jem.192.10.1391. View

Murakami S, Suzuki S, Hanamura I, Yoshikawa K, Ueda R, Seto M . Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro. Hematol Oncol. 2020; 38(5):705-714. DOI: 10.1002/hon.2794. View

10.

Chiu C, Chang J, Dantanarayana A, Solomon A, Evans V, Pascoe R . Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. J Immunol. 2021; 208(1):54-62. PMC: 8702486. DOI: 10.4049/jimmunol.2100367. View

11.

Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J . Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2019; 135(9):597-609. PMC: 7098811. DOI: 10.1182/blood.2019002121. View

12.

Cummins N, Sainski-Nguyen A, Natesampillai S, Aboulnasr F, Kaufmann S, Badley A . Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. J Virol. 2017; 91(11). PMC: 5432861. DOI: 10.1128/JVI.00012-17. View

13.

Rosas-Umbert M, Ruiz-Riol M, Fernandez M, Marszalek M, Coll P, Manzardo C . Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Front Immunol. 2020; 11:418. PMC: 7100631. DOI: 10.3389/fimmu.2020.00418. View

14.

Jans D, Sutton V, Jans P, Froelich C, Trapani J . BCL-2 blocks perforin-induced nuclear translocation of granzymes concomitant with protection against the nuclear events of apoptosis. J Biol Chem. 1999; 274(7):3953-61. DOI: 10.1074/jbc.274.7.3953. View

15.

Hosmane N, Kwon K, Bruner K, Capoferri A, Beg S, Rosenbloom D . Proliferation of latently infected CD4 T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med. 2017; 214(4):959-972. PMC: 5379987. DOI: 10.1084/jem.20170193. View

16.

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

17.

Deeks S, Overbaugh J, Phillips A, Buchbinder S . HIV infection. Nat Rev Dis Primers. 2016; 1:15035. DOI: 10.1038/nrdp.2015.35. View

18.

Collins D, Gaiha G, Walker B . CD8 T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020; 20(8):471-482. PMC: 7222980. DOI: 10.1038/s41577-020-0274-9. View

19.

Deeks S, Archin N, Cannon P, Collins S, Jones R, de Jong M . Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021; 27(12):2085-2098. DOI: 10.1038/s41591-021-01590-5. View

20.

Badley A, McElhinny J, Leibson P, Lynch D, Alderson M, Paya C . Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol. 1996; 70(1):199-206. PMC: 189805. DOI: 10.1128/JVI.70.1.199-206.1996. View